Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. announced the presentation of pivotal clinical trial results for its drug candidate MRG003 at the 2025 ASCO Annual Meeting. MRG003, an innovative ADC targeting epidermal growth factor receptor, showed significant improvements in objective response rate and progression-free survival compared to chemotherapy in patients with recurrent or metastatic nasopharyngeal cancer. The study suggests a potential paradigm shift in treatment, demonstrating meaningful benefits while maintaining a manageable safety profile.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on developing innovative antibody drug conjugates (ADCs) targeting various cancer types, with a market focus on treatments for recurrent or metastatic cancers.
Average Trading Volume: 18,595,893
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.94B
For detailed information about 2157 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue